News - Generics, Global


Current filters:


Popular Filters

1 to 25 of 61 results

European generics group welcomes WHA resolution on biotherapeutics products


The European Generic Medicines Association (EGA) has welcomed the 67th World Health Assembly’s Resolution…


EGA calls for international regulatory cooperation


European Generics Medicines Association (EGA) Director General Adrian van den Hoven last week joined…

GenericsGlobalPharmaceutical industryRegulationResearch

Prosonix and Mylan in deal for Flixotide and Flovent generics


Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

UNITAID helps accessing quality drugs at affordable prices


At an interactive session with Indian pharmaceuticals and diagnostics industry leaders organized by the…


Aid group urges countries not to trade away health as TPP negotiations intensify


The far-reaching Trans-Pacific Partnership Agreement (TPP) should be a force for improving health outcomes…


EU falsified medicines directive: imported active substances need written confirmation to guarantee GMP standards


From July 2, 2013, all active substances manufactured outside of the European Union and imported into…


UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products


UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData


The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Global biosimilar drug revenues will reach $2,445 million in 2013, says Visiongain


The world market for biosimilar drugs will be worth $2,445 million in 2013, growing by more than 20%…

BiotechnologyCellTrionGenericsGlobalHospiraMarkets & MarketingSandoz

Pfenex and Agila Biotech set up JV to develop biosimilars


US biotech firm Pfenex Inc. and Agila Biotech, a subsidiary of Indian drugmaker Strides Arcolab (BO:…

Agila BiotechBayerBetaferonBetaseronBiotechnologyGenericsGlobalNeurologicalPfenexProductionResearchStrides Arcolab

Support for introduction of a global regulatory process for biosimilars


The majority of surveyed US and European physicians and payers are in favor of the introduction of a…


GlaxoSmithKline and A*STAR's ICES to develop medicines for emerging markets


UK pharma giant GlaxoSmithKline (LSE: GSK) and Singapore-based A*STAR's Institute of Chemical and Engineering…


CNS therapeutics market facing downward pressure as branded drugs continue to expire


The global central nervous system (CNS) therapeutics market has been forecast to reach $133 billion by…

GenericsGlobalMarkets & MarketingNeurologicalPharmaceutical

Medicines Patent Pool and ViiV Healthcare collaborate to treat pediatric HIV


The Medicines Patent Pool (MPP) this week announced the launch of a new collaboration with ViiV Healthcare…

AbacavirAnti-viralsGenericsGlobalPatentsPharmaceuticalViiV Healthcare

India to expand presence in global generics market


India plans to significantly expand its presence in the global generics market during the next several…

GenericsGlobalMarkets & Marketing

Generic statins to slash global market value by 2018


The introduction of generic statins has kick-started a decline that will see the global statins market…

Cardio-vascularGenericsGlobalMarkets & Marketing

Sales of antiretroviral agents for HIV will decline slightly over next decade


Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

Major constraints in the hospital-treated infections drug market include generic erosion


The hospital-treated infections (HTI) drug market, the loss of patent protection for key branded products…

Antibiotics and Infectious diseasesGenericsGlobalMarkets & MarketingPharmaceuticalResearch

Big Pharma embraces biologics


Fast-evolving biopharmaceuticals will challenge synthetic market dominance in the global market for active…

BiotechnologyGenericsGlobalMarkets & Marketing

Generic drugs market will reach $127.8 billion in 2013, Visiongain predicts


The value of the world prescription generic drug industry stands at $110.8 billion in 2011 and is forecast…

GenericsGlobalMarkets & MarketingPatents

Migraine drug sales to grow to $5.8 billion in 2021 in major markets


Despite a decline in sales owing to the generic entry of most triptans, the launch of emerging acute…

AllerganBotoxCoLucidGenericsGloballasmiditanLevadexMAP PharmaceuticalsMarkets & MarketingPharmaceuticalResearch

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021


Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

1 to 25 of 61 results

Back to top